相关实验视频

Updated: Jul 25, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

条状投射神经元的轴突末端缩与levodopa诱导的动力障碍原始化

Takashi Nakamura¹, Haruo Nishijima¹, Fumiaki Mori²

¹Department of Neurology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Frontiers in neuroscience

|June 23, 2023

概括

在帕金森氏症大鼠中,重复的乐沃多巴治疗导致了轴突末端的扩大和加大了胺黄油酸 (GABA) 的储存,这表明了乐沃多巴诱导的运动障碍 (LID) 的原始化过程. 这表明GABA积累是发展LID的关键.

科学领域:

神经科学是一个神经科学.
帕金森病研究帕金森病研究
神经药理学神经药理学

背景情况:

在帕金森病中,Levodopa诱导的动力障碍 (LID) 与白球 (GPi) 中的轴突终端扩大与过度的玛-氨基黄油酸 (GABA) 有关.
在服用乐伏多巴后,大规模的GABA释放到GPi中是LID出现的关键因素.

研究的目的:

在帕金森氏症大鼠中,调查LID和轴突末端缩是否会随着重复的Levodopa治疗而逐渐发展.
为了确定这种过度缩是否反映了动力障碍原始化过程.

主要方法:

使用了帕金森病的老鼠模型 (6-氧多巴胺损伤的老鼠).
服用列沃多巴与本塞拉合并3天,7天或14天,或使用额外的化合物 (8-OH-DPAT) 进行14天的治疗.
评估了异常非自愿运动 (AIM) 评分,并检查了GPi中的轴突终端形态.

主要成果:

异常非自愿运动 (AIM) 评分随着重复的勒沃多巴治疗而逐渐增加.
在GPi中,轴突末端缩也随着levodopa治疗而增加.
过度缩小的终端显示了突触囊泡的数量增加.

结论:

在帕金森氏症大鼠中,渐进的乐伏多巴治疗导致动力障碍和轴突末端缩的增加.
观察到的缩和直接途径神经元终端中GABA储存的增加代表了LID发展的原始化机制.

关键词:

对于GABA来说,这是一个很好的选择.异常非自愿的运动是异常的.轴突端子的终端接受了莱沃多巴治疗的老鼠.启动初始化启动初始化突触性可塑性突触性可塑性突触囊泡中的突触囊泡.

更多相关视频

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

相关概念视频

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.